Literature DB >> 1317418

Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouse.

U Alon1, D L Donaldson, S Hellerstein, B A Warady, D J Harris.   

Abstract

To investigate the biochemical nature of nephrocalcinosis in children with hypophosphatemic rickets treated with orally administered phosphate and vitamin D, we studied five such patients, aged 3.7 to 12.3 years, during treatment and again 3 days after it had been discontinued. Treatment was associated with significant increases in mean serum phosphate concentration and urine phosphate/creatinine ratio, from 0.71 to 1.03 mmol/L and from 3.61 to 9.42 mmol/mmol, respectively. Significant correlation was found between urine phosphate/creatinine and oxalate/creatinine ratios (r = 0.670; p less than 0.01); however, the mean urine oxalate/creatinine ratio of 65.0 mumol/mmol while patients were taking phosphate orally was not significantly different from the ratio of 59.0 mumol/mmol when treatment was discontinued. Kidney biopsy specimens from three of the patients showed that the renal calcifications were located mainly intratubularly and were composed exclusively of calcium phosphate. In a further investigation of the nature of phosphate-induced nephrocalcinosis, six 6-week-old male Hyp mice, the murine analog of the human disease, received oral phosphate therapy with drinking water for 48 days; six others served as control animals. Mice in the experimental group excreted more phosphate (p less than 0.001) and less calcium (p less than 0.01) than control mice did, and medullary nephrocalcinosis, with a high kidney calcium content, developed (p less than 0.001). Histologic sections showed that the renal calcifications were located intratubularly and were composed of calcium phosphate. We conclude that, both in children with hypophosphatemic rickets and in the Hyp mouse, the development of nephrocalcinosis is associated with high oral phosphate intake and subsequent deposition of calcium phosphate precipitates in the kidney.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317418     DOI: 10.1016/s0022-3476(05)81957-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  19 in total

1.  Hypophosphatemic rickets: results of a long-term follow-up.

Authors:  Maria Helena Vaisbich; Vera H Koch
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

2.  Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment.

Authors:  Catherine Quinlan; Katie Guegan; Amaka Offiah; Richard O' Neill; Melanie P Hiorns; Sian Ellard; Detlef Bockenhauer; William Van't Hoff; Aoife M Waters
Journal:  Pediatr Nephrol       Date:  2011-11-20       Impact factor: 3.714

3.  Resolution of medullary nephrocalcinosis in children with metabolic bone disorders.

Authors:  Ari Auron; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2005-06-23       Impact factor: 3.714

4.  Histological long-term outcome of furosemide-induced nephrocalcinosis in the young rat.

Authors:  U S Alon; R A Kaplan; L L Gratny; M A Nichols
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

5.  Impaired urinary osteopontin excretion in Npt2a-/- mice.

Authors:  Daniel Caballero; Yuwen Li; Julian Ponsetto; Chuanlong Zhu; Clemens Bergwitz
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-26

6.  Medullary nephrocalcinosis in nephropathic cystinosis.

Authors:  D S Theodoropoulos; T H Shawker; C Heinrichs; W A Gahl
Journal:  Pediatr Nephrol       Date:  1995-08       Impact factor: 3.714

Review 7.  Adverse renal and metabolic effects associated with oral sodium phosphate bowel preparation.

Authors:  Eliot C Heher; Samuel O Thier; Helmut Rennke; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 8.237

Review 8.  Hypophosphatemic rickets due to perturbations in renal tubular function.

Authors:  Maria Goretti M G Penido; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2013-05-01       Impact factor: 3.714

9.  Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease.

Authors:  A Taylor; N H Sherman; M E Norman
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

Review 10.  Therapeutics of X-linked hypophosphatemic rickets.

Authors:  K Latta; S Hisano; J C Chan
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.